This was a lot of fun to record with Divya Shankar! American Thoracic Society (ATS) ATS Crit Care ATS Early Career listen to learn about the work we do on the Critical Care Program Committee and how to get involved in the ATS! #ATS2024

In this issue of Circulation-“Summarizing Primary Results in Clinical Trials with a Time-to-event Endpoint.” This is the first of a series of statistical review articles for cardiologists from Andrea Bellavia and Sabina Murphy, to be published quarterly. ahajournals.org/doi/10.1161/CI…

A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy with A Fully Magnetically Levitated LVAD: The DOT-HM3 Study | Circulation ahajournals.org/doi/10.1161/CI…
The ISHLT plenary presentation! Ivan Netuka Mandeep R. Mehra, MBBS, MSc, FRCP (London) Peter Ivak Zuzana Tucaniva 😀 colleagues

Elderly pts with ASCVD derive similar to greater CV benefit compared to younger pts with early initiation of #evolocumab up to 8.6 yrs with no significant safety concerns. These findings may be helpful in guiding future US recommendations. Samer Alsaid Robert Giugliano #ACC24

Sim Pub w/ #ACC24 in #CircHF by Sid M. Patel et al: Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights from the CCCTN Registry
ahajournals.org/doi/10.1161/CI… #AHAJournals AHA Science Nancy Sweitzer MDPhD Sid M. Patel
TIMI Study Group

Among patients with #T2DM enrolled in the DECLARE-TIMI 58 trial, soluble ST2 is independently associated with higher risk for multiple adverse CV outcomes, with consistent benefit of #dapagliflozin for CVD/HHF across baseline sST2 concentrations Paul M Haller Stephen Wiviott #ACC24

Early serial assessment of vasoactive trajectory 📈identifies a strong gradient of mortality risk across a broad range of patients presenting with CS. #ACC24 #SimPub in Circ: Heart Failure from Sid M. Patel Critical Care Cardiology Trials Network 👇🏽
ahajournals.org/doi/10.1161/CI…

A #SMART -C Collaborative Meta-Analysis

📌Meta-analysis of 78,607 patients shows #SGLT2i reduce MACE by 9% across patients with DM, #HeartFailure , or #CKD .

📌The benefit for CV death was driven primarily by ⬇️ in HF death and SCD (HR 0.68 [0.46-1.02] and HR 0.86 [0.78-0.95],

Astonishing results from the DanGer Shock Trial presented at #ACC24 and out in NEJM today.

In patients with ST-elevation MI with cardiogenic shock, Impella reduced all-cause mortality (45.8% Impella vs. 58.5% control) at 180 days.

Some thoughts on this ground breaking trial:

.Brian Bergmark shares the breakthroughs in BRIDGE-TIMI 73a

#ESCTVOnTheRoad #ACC24

👉🏼 SGLT2i ⬇️ risk of MACE across broad range of pt populations & key subgroups 👉🏼 Benefit primarily driven by ⬇️ CV death, particularly ⬇️ HF death & SCD #SimPub in Circulation from Sid M. Patel Yumi Kang, MD, PhD Stephen Wiviott SGLT2 Trialists Consortium #ACC24
ahajournals.org/doi/10.1161/CI…

🔥🔥🔥DanGer Shock shocks the 🌎 Congrats to Dr Jacob Møller & colleagues on executing this trial! So much to learn & unpack. #ShockFam How will these results change your clinical practice? 🤔 Navin Kapur Manreet Kanwar Jaime Hernandez-Montfort A. Reshad Garan MD Dan Burkhoff MD PhD Jason N. Katz

In patients with TGs >150 mg/dL and high CV risk, apoC-III inhibitor olezarsen reduced TG levels by ~50%.

Olezarsen also reduced apoB and non-HDL-C, markers of atherogenic risk.

Proud to be a part of this team.

Full paper now in NEJM.

TIMI Study Group Brian Bergmark

#ACC24 #SimPub in Circulation by Sid M. Patel & #SMARTc investigators

Massive effort evaluating 78,607 patients across 11 late-phase trials in diabetes, CKD, & HF providing definitive evidence of the effects of #SGLT2i on #MACE

ahajournals.org/doi/10.1161/CI…

#CircACC24 #SimPub SGLT2i Trialists Consortium: primary benefit of SGLT2i for MACE driven by reduction in CV death, without clear effect on myocardial infarction or stroke Sid M. Patel TIMI Study Group #AHAJournals ahajournals.org/doi/10.1161/CI…

New SMART-C data #simpub in Circulation

SGLT2i ⬇️major CV events by 9%, mainly by ⬇️CV death,  no clear effect on MI or stroke

14% ⬇️CV death driven by heart failure & sudden cardiac death

Remarkably consistent benefits across key patient groups

ahajournals.org/doi/10.1161/CI…

#ACC24

Terrific talk by Erin Bohula on complications with MCS devices #ACC24 Sandeep Nathan, MD, MSc Frederick Welt Angela Lowenstern Jason Wollmuth David Berg Brian Bergmark

Join us tomorrow at #ACC24

Pooled data from the SGLT2i Consortium (SMART-C) on the effects of SGLT2i on major CV events & cause-specific cardiovascular mortality in major patient groups (including with & without prior MI)

Led by Sid M. Patel Stephen Wiviott & TIMI Study Group #ACC24

Just in time to listen as you travel to ATL, the #ACC24 preview epi of #TIMITalks is now out! Douglas Drachman, Chair of the American College of Cardiology Scientific Sessions, joins the podcast to discuss highlights & share tips on getting the most out of ACC. Nicholas Marston David Berg Mass General Heart

💡A patient presents to your clinic with new AF detected solely by their pacemaker (or ⌚️) - does this warrant anticoagulation?

Very important study in Circulation by William F McIntyre from NOAH-AFNET6 & ARTESiA
ahajournals.org/doi/10.1161/CI…

Our accompanying editorial: ahajournals.org/doi/10.1161/CI…